Latest News
-

A road less traveled: how making less huntingtin can alter somatic instability and may delay symptoms
CAG repeats can get longer over time as the HD gene is used, like the growing potholes and cracks in an old road. New research finds that blocking cells from using their HTT gene slows this wear and tear, which might slow the onset of symptoms in HD.
-

Huntington's Disease Therapeutics Conference 2016 – day 3
Stem cells and modeling Huntington's disease in our final Therapeutics Conference report
-

Huntington's Disease Therapeutics Conference 2016 – day 2
Strategies for getting rid of mutant huntingtin & clinical trial updates: day 2 of the HD therapeutics conference
-

Huntington's Disease Therapeutics Conference 2016 – day 1
Proteins and DNA – Jeff and Ed report from day 1 of the 2016 #huntingtonsdisease therapeutics conference
-

Looking Past the Spin: Results from a Clinical Trial of Cysteamine
Phase 2/3 clinical trial results prove inconclusive for Huntington's drug cysteamine.
-

A recycled drug gives us new insight in to HD
An existing drug could give a boost to HD brain cells – but it may need more testing before it’s back in the clinic
-

Through the eyes of a friend: changes in mood and behavior in early HD
Companions of HD gene carriers are more likely to notice psychological changes in presymptomatic HD.
-

A multiple sclerosis drug that works for Huntington's disease: the real deal or too good to be true?
Fingolimod, a drug used in multiple sclerosis, prevents memory problems in HD mice. Would it work in patients?
-

Mapping the anatomy of HD: a whole-brain history
A new book for researchers describes a century of HD anatomy and presents evidence that HD affects the whole brain.


